Top Stories

Follow us: ChinaBio

"Mr. Bio in China"

Free from Nature

>> Download now...

Week in Review

In My Opinion

Free Articles

Education Center

Interfax-BW Releases

Recent Articles

China Excitement at J.P. Morgan Healthcare Conference Jan 14, 2012: The annual J.P. Morgan Healthcare extravaganza, held last week in San Francisco, was buzzing with excitement about China. Optimism was running high and, best of all, participants were discussing real deals. It was the second year the conference included a China-specific track, giving 15 China-centered life science companies a chance to present their stories. The room was often filled to its 200-seat capacity, forcing some attendees to stand at the back and even more to peer in through the glass doors at the back of the room. The strong sense of positive energy evident throughout J.P. Morgan this year was even more apparent in the China Reception following the company presentations. More details....

Share this with colleagues:

China Announces Major Program for Biotechnology 2010-2020 Jan 5, 2012: To establish itself in the global front rank of biotech innovation, China has issued the National Program on Bioscience Technology Development 2010-2020. The program, which was issued by the Ministry of Science and Technology, establishes a series of ambitious, very specific goals for developing a world-class biotech industry in China. As a starter, China wants to produce three to five top biotech scientists with international reputations and Nobel Prize potential by 2020. More details....

Share this with colleagues:

China Supports Foreign Direct Investment in Biotechnology Dec 30, 2011: China issued new rules that will encourage foreigners to invest in China biotechnology companies. Because biotechnology is a favored industry, foreign direct investments in the sector will be subject to a lower level of administrative scrutiny and may also qualify for preferential tax treatment and other benefits. More details....

Share this with colleagues:

Merck Will Build Beijing R&D Center; Invest $1.5 Billion in China Dec 6, 2011: Merck announced plans to build an Asia Research & Development headquarters in Beijing, which will be devoted to innovative drug discovery and development. The new initiative is part of a broader $1.5 billion investment in China R&D that Merck will make over the next five years. Merck said the investment has two goals: building its own capabilities and fostering relationships with outside researchers. It expects the center to provide new drugs and vaccines that meet global needs. More details....

Stock Symbol: (NYSE: MRK)

Share this with colleagues:

China's 12th Five-year Plan for Medical Technology Dec 2, 2011: China has released its 12th Five-year Plan for Medical Technology, setting a long list of broad goals to be accomplished by the end of 2015. Those goals range from discovering world-leading medical technology to establishing robust means of diagnosing and treating China’s rural population, who live far from the country’s high-tech hospitals in urban centers. This Plan does not mention how much financial support each of the goals will receive, but it does lay out the country’s agenda for 2011-15. More details....

Share this with colleagues:

China Plans $1.7 Trillion Investment in Hi-Tech, including Biotechnology Nov 21, 2011: China will invest 10 trillion RMB ($1.7 trillion) over the next five years into five strategic industries – one of which is biotechnology. The program and the amount were announced by US Commerce Secretary John Bryson, who is visiting China on an official trade mission. The program was reported for the first time one year ago in a Reuters report, but it was never officially confirmed. More details....

Share this with colleagues:

Roche’s Strategy for China – Global, Not Local Oct 30, 2011: When asked to describe Roche’s strategy for China, Dr. Joe McCracken, Global Head of Business Development for the Swiss pharma, disarmingly answered “We don’t have one.” But he didn’t mean Roche has no strategy for China. “China is part of our global strategy and everything China does is related to our global strategy,” he explained in an exclusive interview with ChinaBio® Today in Shanghai. More details....

Stock Symbol: (SIX: ROG)

Share this with colleagues:

SFDA Annual Report of Drug Registration Approvals -- 2010 Oct 21, 2011: The SFDA has released a concise summary of its registration approvals last year, showing, to nobody's surprise, that China's pharmaceutical scene is active -- the number of approvals numbered exactly 1,000. To make the data more useful, we have broken it down using various metrics, presenting, for example, the totals by type of drug (chemical, TCM, biologic), the number of clinical trials approved, and the number of registration applications that were submitted. All of the data is contained in the eight tables. More details....

Share this with colleagues: